Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Outcomes in Black and White Patients With mRCC Treated With First-Line TKIs
  2. Promising Activity of Pembrolizumab + Bevacizumab in mRCC
  3. Improved Time to Treatment Failure and OS Are Observed in Patients With Longer Time to Metastasis
  4. The Apparent Diffusion Coefficient Predicts Early Therapeutic Response in mRCC
  5. Predictive Biomarkers in Metastatic Renal Cell Carcinoma
  6. First-Line Rocapuldencel-T + Sunitinib Does Not Improve OS in mRCC
  7. Female Gender Predicts Favorable Prognosis in Patients With Nonmetastatic ccRCC Undergoing Curative Surgery
  8. Adjuvant FGFR3 Inhibition in Bladder Cancer
  9. Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma
  10. Overall Survival From Extended Follow-Up of a Trial of Nivolumab and Ipilimumab for the First-Line Treatment of Advanced Renal Cell Carcinoma

Elsewhere

Recently Updated